Similarly, studies in breast tumor xenografts generated by ErbB-2 positive BTA474 breast cancer cells suggested that the combination of trastuzumab with GSI could decrease the recurrence of ErbB-2-positive breast tumors and may be beneficial in the treatment of recurrent trastuzumab-resistant disease [216]. The gene discussed is ERBB2; the disease is breast neoplasm.